FDA Goes After Hereditary Angioedema (DYAX)
Dyax Corp. (NASDAQ:DYAX) announced after the close that the FDA’s Pulmonary-Allergy Advisory Committee voted in favor of approval of DX-88 for the treatment of acute attacks of hereditary angioedema....
View ArticleDyax (DYAX) Rockets Up
Dyax Corp. (NASDAQ: DYAX) shares are rising 28% at $4.47 after the comapny won FDA approval to market its Kalbitor for the treatment of genetic hereditary angioedema in patients 16 years and up. This...
View ArticlePharma-Biotech Major Research Alerts (TEVA, AMGN, ACOR, CELG, HGSI, BIIB,...
Biotech and pharma research calls from Wall Street research firms have come out of the wood work this Thursday. Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is one of our recent “Defensive...
View Article
More Pages to Explore .....
